文献速递肺血管病与心包/心肌炎

2017 ACC/AAP/AHA卫生政策声明:从西地那非经验看儿科药物开发的机遇与挑战

2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.
PubMed 文献 · J Am Coll Cardiol · 2017-06-29

该声明由FDA代表与JCCHD(代表ACC、AHA、AAP的儿科心脏病领导层)联合制定,基于STARTS-1和-2试验及2012年FDA对西地那非用于儿科肺动脉高压的标签,描述当前环境并识别减少儿科药物试验障碍的可能未来方向。

要点

  • STARTS-1和-2试验及2012年FDA标签凸显儿科药物开发与审批的挑战。
  • FDA与JCCHD合作旨在改善沟通并协调儿科药物试验使命。
  • 声明识别减少儿科药物试验障碍的可能未来方向。

核心结论

  • 基于西地那非在儿科肺动脉高压中的经验,FDA与JCCHD联合声明提出减少儿科药物试验障碍的未来方向。

研究设计与样本

  • 由FDA代表与JCCHD(代表ACC、AHA、AAP的儿科心脏病领导层)联合制定的卫生政策声明。

主要发现

  • STARTS-1和-2试验及2012年FDA对西地那非儿科肺动脉高压的标签凸显了儿科药物开发与审批的诸多挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The STARTS-1 and -2 trials (Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension) and subsequent 2012 U.S. Food and Drug Administration (FDA) product labeling for sildenafil use in pediatric patients with pulmonary hypertension highlight many of the challenges to the development and approval of medications for children. This experience served as the impetus for direct collaboration between FDA representatives and the Joint Council on Congenital Heart Disease (JCCHD) (representing the pediatric cardiology leadership of the American College of Cardiology, the American Heart Association, and the American Academy of Pediatrics) to improve communication and realign missions with regard to pediatric drug trials. These discussions led to the joint FDA/JCCHD development of this statement, which describes the current environment and identifies possible future directions for reducing barriers to pediatric drug trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sable CA, Ivy DD, Beekman RH, et al. 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. J Am Coll Cardiol. 2017. PMID: 28669447. doi:10.1016/j.jacc.2017.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。